The majority of clinical trials target only a few conditions (i.e., nephrotic syndrome, migraine, rosacea, cluster headache, major depression) and apply PACAP as a challenge agent, investigate its role to initiate disease, or test its involvement. Here, ADCYAP1 is linked to major depressive disorder.